You need to enable javascript for this functionality

 

SLDC support GSK Investment with unique Local Development Order


24 August 2011

South Lakeland District Council is backing a bid by global pharmaceutical giant, Glaxosmithkline (GSK) to bring major investment to the company’s site at Ulverston in South Cumbria.

GSK have signalled they wish to invest more than five hundred million pounds in a hi-tech biopharmaceutical plant in the UK, and the company’s existing site in Ulverston is one of four potential sites competing for this major investment.  The Government is currently consulting on Patent Box legislation, which will cut corporation tax on Research and Development in the UK to only 10%. 

SLDC is doing everything within its power to ensure that Ulverston secures this huge capital investment, which would attract high value high tech jobs to Ulverston, South Lakeland and Cumbria.

At a recent Cabinet meeting, SLDC pledged to streamline the planning process by progressing a pioneering Local Development Order (LDO).  This is a different way of granting planning permission for a new manufacturing plant on the existing site and means that planning regulations will be relaxed.  The council will also waive planning fees that could have been in the region of between £45,000 to £92,000.

Councillor Graham Vincent, portfolio holder for Enterprise and Economy, said: “This is a fantastic opportunity to be grasped with both hands.  The investment potential is incredible as it could bring around £10m into the South Lakeland economy every year.  The council will be fighting hard to win this and will do everything in its power to help and support Glaxosmithkline with their plans.” 

This will be the first LDO to be created in Cumbria and underlines the council’s commitment to ensuring that GSK Ulverston is well placed to attract the potential investment. The LDO would be issued as a ‘one off’ as the council aims to support this major opportunity to attract significant investment to Ulverston and South Lakeland.  

GSK are looking at four existing sites in the UK and Ulverston, Barnard Castle, Montrose and Irvine in Scotland will be considered first.  SLDC officers are working closely with GSK Ulverston to make sure the best proposal is presented in terms of skills, community support, education, housing, culture and environment.  This will underpin the benefits of building a new plant in Ulverston and show the council’s overwhelming support for this investment